Literature DB >> 17500

Methadone maintenance: effect of urinary pH on renal clearance in chronic high and low doses.

G D Bellward, P M Warren, W Howald, J E Axelson, F S Abbott.   

Abstract

The subjects were 12 male patients stabilized on methadone for many months or years. A comparison was made of the plasma levels and renal clearance of methadone between patients on "high" doses (80 to 110 mg/day) and those on "low" doses (15 to 40 mg/day). A general trend to higher renal clearance was seen in the "high" -dose group, but on more detailed examination there was a direct correlation only when the patients were categorized by urinary pH. At low pHs, there was nearly a 3-fold increase in renal clearance which was associated with a decreased major metabolite to methadone ratio. No evidence for a difference in rate of metabolism between the two groups was found nor were there differences in hepatic function. It was concluded that urinary pH was a major factor in renal clearance of methadone.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 17500     DOI: 10.1002/cpt197722192

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

Review 1.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 2.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Methadone for Pain Management: A Pharmacotherapeutic Review.

Authors:  Denise Kreutzwiser; Qutaiba A Tawfic
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

4.  Steady-state pharmacokinetics of methadone in opioid addicts.

Authors:  K Wolff; A W Hay; D Raistrick; R Calvert
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Evaluation of an enzyme immunoassay for the detection of methadone metabolite EDDP [2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine] in urine.

Authors:  Carl E Wolf; Ashley Goldstein; Justin L Poklis; Alphonse Poklis
Journal:  J Clin Lab Anal       Date:  2014-01-06       Impact factor: 2.352

6.  Relationship between methadone and EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine) in urine samples from Norwegian prisons.

Authors:  Jean-Paul Bernard; Mimi Stokke Opdal; Ritva Karinen; Jørg Mørland; Hassan Z Khiabani
Journal:  Eur J Clin Pharmacol       Date:  2007-06-19       Impact factor: 2.953

7.  Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts.

Authors:  J W de Vos; P J Geerlings; W van den Brink; J G Ufkes; H van Wilgenburg
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

8.  Effect of urinary pH on the disposition of methadone in man.

Authors:  M I Nilsson; E Widerlöv; U Meresaar; E Anggård
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

Authors:  Mohammad-Reza Shiran; Martin S Lennard; Mohammad-Zafar Iqbal; Oldwale Lagundoye; Nicholas Seivewright; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

10.  Pharmacokinetics of methadone during maintenance treatment: adaptive changes during the induction phase.

Authors:  M I Nilsson; E Anggård; J Holmstrand; L M Gunne
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.